Full Breakdown
Alibaba and AUS Merchant Services Pay $600 Million to Resolve U.S. DOJ Probe into Illegal Drug Sales
7/2/2026, 8:37:21 PM
Settlement Overview
The U.S. Department of Justice announced that Alibaba Group Holding Ltd. and its U.S. payment affiliate AUS Merchant Services Inc. will pay a combined $600 million to settle allegations that their platforms enabled roughly 80,000 unlawful sales of prescription drugs, controlled substances, regulated chemicals and pill-pressing equipment into the United States. The parties entered non-prosecution agreements, with Alibaba liable for a $125 million criminal fine and $200 million forfeiture, and AUS Merchant Services for an $85 million fine and $190 million forfeiture.
Regulatory Background and Prior Issues
The investigation, spanning 2016-2024, focused on violations of the Federal Food, Drug, and Cosmetic Act. Federal agents from the FDA, IRS Criminal Investigation, the U.S. Postal Inspection Service and other agencies conducted more than 40 undercover purchases that confirmed the illicit flow of products through Alibaba.com and AliExpress.com. Internal Alibaba employees repeatedly raised concerns that compliance controls were inadequate, yet the company’s messaging system allowed sellers to divert buyers to off-platform channels, evading detection.
Principal Entities and Officials
- Alibaba Group Holding Ltd. – Operator of Alibaba.com and AliExpress.com, the world’s largest cross-border e-commerce platforms.
- AUS Merchant Services Inc. – U.S. payment processor formerly known as Alipay U.S., responsible for transaction settlement.
- Brett Shumate – Assistant U.S. Attorney General, DOJ spokesperson on the case.
- Charles C. Calenda – First Assistant U.S. Attorney, District of Rhode Island.
- Jarod Koopman – Chief, IRS Criminal Investigation Division.
Scope and Scale of Violations
- Approximate illegal transactions: 80,000 (Jan 2016 – Dec 2024)
- Gross merchandise value of prohibited sales: > $200 million
- Undercover purchases: > 40 successful acquisitions of illicit drugs or counterfeiting equipment
- Financial penalties: $600 million total, split as described above
Official Statements & Responses
The DOJ emphasized that marketplace operators must “implement appropriate safeguards” and will be held accountable for failures. Alibaba’s spokesperson described the settlement as a “mutually satisfactory resolution” that will bring “stricter compliance” and noted the company’s full cooperation. AUS Merchant Services acknowledged shortcomings in its anti-money-laundering program and pledged to enhance transaction monitoring. Both entities committed to ongoing cooperation with federal investigators and to upgrading their compliance frameworks.
Criticism & Opposition
U.S. prosecutors criticized Alibaba for allowing merchants to bypass internal controls, citing internal employee warnings that were not acted upon. The DOJ highlighted the “systemic breakdown” that let illegal pharmaceuticals reach U.S. consumers, while the IRS underscored the firm’s duty to safeguard consumers from dangerous products.
Why It Matters
The settlement, the largest monetary resolution against a Chinese e-commerce firm in a U.S. federal action, signals heightened enforcement of the FDCA on cross-border digital marketplaces. It also sets a precedent for holding payment processors accountable for facilitating prohibited transactions, potentially prompting stricter global compliance standards for online platforms.
Verbatim Quotes
- “Today’s resolution reflects the Department of Justice’s commitment to ensuring that companies operating e-commerce and digital payment platforms keep illegal, unapproved, misbranded, and dangerous foreign pharmaceuticals off their marketplaces.” — Brett Shumate, Assistant U.S. Attorney General
- “As one of the world’s largest online retailers, Alibaba has an obligation to safeguard consumers from dangerous and illegal products, and to maintain integrity throughout its payment processes,” — Jarod Koopman, Chief, IRS Criminal Investigation Division
- “holding companies accountable when their platforms are used to facilitate the unlawful sale of illegal pharmaceuticals, related pharmaceutical equipment and other prohibited products in the US” — Charles C. Calenda, First Assistant U.S. Attorney, District of Rhode Island
- “Alibaba reached a mutually satisfactory resolution with U.S. regulators on bringing stricter compliance to the sale of products in the United States by third-party merchants on its e-commerce platforms,” — Alibaba spokesperson
- “Companies operating online marketplaces — whether based in the United States or abroad — must implement appropriate safeguards to prevent bad actors from exploiting their platforms,” — Brett A. Shumate, Assistant Attorney General
What’s Next
The non-prosecution agreements require Alibaba and AUS Merchant Services to submit periodic compliance reports, upgrade seller-screening algorithms, and maintain active cooperation with U.S. law-enforcement. Federal agencies have indicated they will monitor the effectiveness of these measures and may pursue further action if violations recur.
